Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "castration-resistant" Clear all
Completed No phase listed Observational

An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States

NCT06204302
View directory record Official record
Conditions
Non-metastatic Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer
Interventions
Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 23, 2026, 6:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

NCT03837353
View directory record Official record
Conditions
Prostate Cancer
Interventions
DKN-01, Docetaxel
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

NCT01084655
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700, Docetaxel, Prednisone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

NCT03511664
View directory record Official record
Conditions
Prostate Cancer
Interventions
177Lu-PSMA-617, Best supportive/best standard of care
Drug · Other
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
45
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

NCT01750398
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Testosterone cypionate, Goserelin, Leuprolide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

NCT02494921
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel-PNP, Ribociclib, Prednisone, Filgrastim
Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Jul 23, 2026, 6:24 PM EDT
Withdrawn Phase 2 Interventional

Docetaxel Followed by Provenge in Metastatic Prostate Cancer

NCT02793765
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Sipuleucel-T
Drug · Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Jul 23, 2026, 6:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

NCT01688492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
3
States / cities
Evanston, Illinois • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 23, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

NCT06039371
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Etoposide, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate, Radioconjugate, Dual X-ray Absorptiometry, Gallium Ga 68-PSMA-617, Positron Emission Tomography, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06052306
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BAY3546828
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
5
States / cities
Duarte, California • Minneapolis, Minnesota • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

NCT04288687
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Niraparib Pill
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

NCT01540071
View directory record Official record
Conditions
Castration Resistant Prostate Cancer
Interventions
NRX 194204
Drug
Lead sponsor
Io Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 23, 2026, 6:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324
View directory record Official record
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
PF-06821497, Docetaxel, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
71
States / cities
Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

NCT06574880
View directory record Official record
Conditions
Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer
Interventions
Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Angela Y. Jia, MD PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

NCT06609005
View directory record Official record
Conditions
Advanced Metastatic Castration Resistant Prostate Cancer
Interventions
INV-9956
Drug
Lead sponsor
Shenzhen Ionova Life Sciences Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Scottsdale, Arizona • Newport Beach, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

NCT01942837
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
5
States / cities
Boston, Massachusetts • Weymouth, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Jul 23, 2026, 6:24 PM EDT
Terminated Phase 2 Interventional Results available

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

NCT03531827
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Interventions
enzalutamide, CRLX101
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 23, 2026, 6:24 PM EDT
Terminated Phase 2 Interventional Results available

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer

NCT01338012
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Laguna Hills, California • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jul 23, 2026, 6:24 PM EDT
Terminated Phase 1 Interventional

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

NCT02349139
View directory record Official record
Conditions
Cancer of the Prostate, Neoplasms, Prostate, Prostate Cancer, Prostatic Cancer, Neoplasms, Prostatic, Prostate Neoplasms, Castration-resistant
Interventions
ASN001: Escalating dose Part A
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Detroit, Michigan • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jul 23, 2026, 6:24 PM EDT
Temporarily Not Available No phase listed Expanded access

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06033001
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer
Interventions
[Lu-177]-PNT2002
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
U.S. locations
7
States / cities
Newport Beach, California • Hartford, Connecticut • Jupiter, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 23, 2026, 6:24 PM EDT
Active, not recruiting Phase 3 Interventional

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

NCT05204927
View directory record Official record
Conditions
Metastasis From Malignant Tumor of Prostate
Interventions
177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Tucson, Arizona • Fullerton, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 23, 2026, 6:24 PM EDT
Terminated Phase 2 Interventional

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

NCT03442556
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 23, 2026, 6:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

NCT04455750
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
414
States / cities
Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 1 Interventional

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

NCT02740985
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions
AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Jul 23, 2026, 6:24 PM EDT